Anthony R Mato

12PUBLICATIONS
102CO-AUTHORS
Molecular targetsPredictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 22, 2026
Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors.

|Mar 14, 2025
Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia.

Yanping Yin, Haifeng Xu, Liye He

|May 16, 2023
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.

Michael L Wang, Wojciech Jurczak, Pier Luigi Zinzani

|Sep 20, 2022
Approach to a patient with "double refractory" chronic lymphocytic leukemia: "Double, double toil and trouble" (Shakespeare).

Julia H Aronson, Sigrid S Skånland, Lindsey E Roeker

|Sep 14, 2022
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Christine E Ryan, Matthew S Davids, Richard Hermann

|Aug 23, 2022
Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia.

Yanping Yin, Paschalis Athanasiadis, Linda Karlsen

Pageof 2

Frequent Collaborators

3 joint publications

Nirav N Shah

2 joint publications

Yanping Yin

2 joint publications

Lindsey Roeker

2 joint publications

Jennifer R Brown